<div id="readability-page-1"><p>Squarepoint Ops LLC raised its holdings in shares of  Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) by 77.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor  owned 148,681 shares of the company's stock after acquiring an additional 64,956 shares during the quarter. Squarepoint Ops LLC owned approximately 0.08% of Legend Biotech worth $5,277,000 as of its most recent filing with the Securities and Exchange Commission.</p><div><p><span></span><span>Get <strong>Legend Biotech</strong> alerts:</span></p></div><ul><li>CPI Data Sparks Rally in Biotech Stocks</li></ul><p>Several other institutional investors and hedge funds also recently modified their holdings of LEGN. PNC Financial Services Group Inc. raised its position in shares of  Legend Biotech by 193.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,916 shares of the company's stock worth $167,000 after purchasing an additional 3,238 shares during the last quarter.  Deutsche Bank AG lifted its position in shares of  Legend Biotech by 2.7% in the first quarter. Deutsche Bank AG now owns 138,656 shares of the company's stock valued at $4,705,000 after acquiring an additional 3,589 shares in the last quarter.  Nuveen LLC acquired a new stake in shares of  Legend Biotech during the first quarter valued at $5,774,000.  Public Sector Pension Investment Board increased its position in  Legend Biotech by 17.8% during the 1st quarter. Public Sector Pension Investment Board now owns 27,789 shares of the company's stock worth $943,000 after purchasing an additional 4,200 shares in the last quarter.  Finally, Brooklyn Investment Group raised its stake in  Legend Biotech by 1,114.8% in the 1st quarter. Brooklyn Investment Group now owns 1,725 shares of the company's stock valued at $59,000 after purchasing an additional 1,583 shares during the last quarter. Hedge funds and other institutional investors own  70.89% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>A number of brokerages recently issued reports on LEGN. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Legend Biotech in a research report on Monday, December 8th. Morgan Stanley dropped their target price on Legend Biotech from $83.00 to $50.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday. JPMorgan Chase &amp; Co. decreased their price target on Legend Biotech from $78.00 to $76.00 and set an &#34;overweight&#34; rating on the stock in a research note on Thursday, October 9th. Royal Bank Of Canada  reaffirmed an &#34;outperform&#34; rating and set a $74.00 price objective on shares of Legend Biotech in a research note on Monday, December 8th. Finally, Barclays dropped their price target on shares of Legend Biotech from $94.00 to $90.00 and set an &#34;overweight&#34; rating for the company in a research report on Thursday, November 13th. Ten equities research analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has issued  a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $68.20.</p><ul><li>Why Legend Biotech Stock Is Having Its Best Month Yet</li></ul><p><b>Get Our Latest Report on LEGN</b></p><h2>Legend Biotech Price Performance</h2><p>Shares of LEGN stock opened at $22.32 on Monday. The firm has a fifty day simple moving average of $29.98 and a 200-day simple moving average of $33.83. The company has a market capitalization of $4.12 billion, a PE ratio of -34.34 and a beta of 0.09. Legend Biotech Corporation Sponsored ADR has a twelve month low of $22.27 and a twelve month high of $45.30. The company has a current ratio of 2.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.17. </p><p>Legend Biotech (NASDAQ:LEGN - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. Legend Biotech had a negative net margin of 26.37% and a negative return on equity of 24.47%. The firm had revenue of $272.33 million for the quarter, compared to analyst estimates of $277.91 million. During the same quarter in the previous year, the business posted ($0.34) EPS. The firm's revenue was up 70.0% compared to the same quarter last year.  Equities research analysts anticipate that  Legend Biotech Corporation Sponsored ADR will post -1.31 earnings per share for the current fiscal year. </p><h2>Legend Biotech Profile</h2> (Free Report)<p>Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Legend Biotech</li><li>Stock Splits, Do They Really Impact Investors?</li><li>3 Underrated Robotics Stocks Poised for Huge Gains</li><li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li><li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li><li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li><li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEVHTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Legend Biotech Right Now?</h2><p>Before you consider Legend Biotech, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.</p><p>While Legend Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LEGN

<p>Squarepoint Ops LLC increased its holdings in Legend Biotech Corporation by 77.6% in Q2, owning 148,681 shares valued at $5.28 million. Other institutional investors also adjusted their positions. Legend Biotech's stock has a 'Moderate Buy' rating with a target price of $68.20. The company reported Q3 earnings with a revenue increase of 70% year-over-year, despite a negative net margin. Legend Biotech focuses on novel cell therapies for oncology.</p>

Squarepoint Ops LLC Grows Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN